[Skip to Content]
[Skip to Content Landing]
Citations 0
August 13, 2003

Long-term Use of Hydroxyurea for Sickle Cell Anemia—Reply

Author Affiliations

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;290(6):754. doi:10.1001/jama.290.6.754-a

In Reply: We agree with Dr Killestein and colleagues that there are several reasons why our results may differ from those of their brief trial among older patients with multiple sclerosis. These include not only study design, degree and duration of exposure to cannabinoids, and dose and contents of the cannabinoid preparations, but also route of administration and ages of the participants. Nonetheless, we believe that the most important difference is that we studied healthy participants with a history of cannabinoid use. By contrast, Killestein et al1 examined patients with longstanding multiple sclerosis, a disease related to immune dysfunction.2